

"Plasminogen activators having a reduced capacity to
bind lysine"

5 The invention relates to an advantageous use of plasminogen activators and claims the priority of German patent application 103 42 518.7, the content of which is hereby incorporated by reference.

10 The establishment of thrombolysis as a therapy option in connection with various thromboembolic diseases is regarded as having been largely concluded. The main interest in thrombolysis research is therefore directed toward the further development and modification of known thrombolytics and/or the improvement of
15 concomitant therapies.

A thrombolytic which is important for taking as a starting point for developing new thrombolytics is tissue plasminogen activator (t-PA), which has a higher
20 fibrin selectivity and a superior activity in comparison with streptokinase or urokinase. The deletion mutants reteplase and lanoteplase, as well as tenecteplase, are further developments of this plasminogen activator.

25 Tissue plasminogen activator (rt-PA) is a single-chain glycoprotein composed of 527 amino acids. The molecule which is initially single-chain (sct-PA) is cleaved by proteolysis into a two-chain form (tct-PA). t-PA
30 possesses defined structural and functional domains. Thus, the N-terminal constituent chain comprises the finger domain (F, Ser1-Lys49), the epidermal growth factor domain (E, Ser50-Asp87) and two kringle domains (K1, Thr88-Gly176; and K2, Asn177-Cys261). The C-
35 terminal chain, which includes a serine proteinase domain (P), comprises amino acids Ser262 to Pro527. By means of the amino acids His322, Asp371 and Ser478, the C-terminal chain forms the active center.

t-PA and its recombinant variants, and their preparation, are the subject, for example, of US patent 4,766,075 and a large number of publications (e.g. Bode and Renatus: Tissue-type plasminogen activator: variants and crystal/solution structures demarcate structural determinants of function, Current Opinion in Structural Biology 1997, 7: 865-872). A diagram of the structure of t-PA is enclosed as Fig. 1.

10

Like most other trypsin-like serine proteinases, sct-PA is converted into the tct-PA form by cleavage. The cleavage takes place at the bond between Arg275 and Ile276. After that, the two chains are then only held together by way of a single disulfide bridge between serine 264 and serine 395.

15

This numbering of the t-PA cleavage site corresponds to that chosen by Bode and Renatus (loc. cit). However, other authors use a different numbering as a basis and define the cleavage or activation site as R15-I16 or R310-I311. However, the sites which are defined in this way do not differ functionally or structurally.

20

Tissue plasminogen activator (t-PA; alteplase) is able to activate plasminogen, which is transformed into plasmin. However, it is evident from kinetic constants that t-PA is only able to activate circulating plasminogen weakly. The two t-PA forms, i.e. both the single-chain molecule and the two-chain molecule, exhibit what are in principle the same pharmacological properties. However, fibrin-bound plasminogen is activated with a catalytic potency which is three powers of ten higher than that with which free plasminogen is activated. Accordingly, the thrombolytic property of tissue plasminogen activator is very greatly augmented by the presence of fibrin.

30

35

A factor of from 500 to 1000 is reported for the relative fibrin selectivity of t-PA. The catalytic effect can also be increased by interaction of plasminogen activator with beta-amyloid or fibrinogen.
5 The ability of t-PA to be activated by fibrinogen is comparable to its ability to be activated by beta-amyloid.

The effect of plasminogen activator is controlled
10 physiologically by inhibitors, with plasminogen activator inhibitor I (PAI-1) being the important antagonist. The binding of PAI-1 to the light constituent chain of the t-PA molecule alters the structure of the catalytic center such that an
15 activation reaction with plasminogen can no longer take place (Bennet WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller M: High resolution analysis of functional determinants in human tissue-type plasminogen activator. Journal of Biological
20 Chemistry 1991; 266: 5191-5201).

Tissue plasminogen activator is metabolized rapidly via the liver. Hepatic insufficiency in a patient therefore prolongs the plasma half-life of the substance
25 (Emeis JJ, van den Hoogen CM, Jense D: Hepatic clearance of tissue-type plasminogen activator in rats, Thomb Haemostas 1985; 54: 661-664; Tiefenbrunn AJ, Robison AK, Kurnik PB, Ludbrook PA, Sobel BE. Clinical pharmacology in patients with evolving myocardial
30 infarction of tissue plasminogen activator produced by recombinant DNA technology Circulation 1985; 71: 110-116).

Plasminogen activators are developed for treating
35 thrombotic diseases such as cardiac infarction and stroke. t-PA is currently the only thrombolytic which is approved by the Food and Drug Administration (FDA) in the USA for treating stroke.

Nevertheless, suspicions have increased in the past that, while t-PA on the one hand exhibits the expected positive thrombolytic effects in connection with treating the stroke, it is on the other hand also
5 responsible for an undesirable destruction of tissue. Thus, infusing t-PA into t-PA-deficient mice gave rise to larger infarctions (Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA: Tissue plasminogen activator (tPA) increases neuronal damage
10 after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4(2): 228-231). It is suspected that these enlarged lesions are due to stimulation of the NMDA-dependent glutamate receptors (Liberatore GT, Samson A, Bladin C, Schleuning WD,
15 Medcalf RL: Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34(2): 537-543). A proteolytic cleavage of the NMDA receptor by t-PA could be responsible for this effect (Nicole O,
20 Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al: The proteolytic activity of tissue plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7(1): 59-64).

25 The object of the present invention is therefore to provide a novel therapeutic treatment of thrombotic diseases, in particular of stroke.

This object is achieved by using a plasminogen-
30 activating factor which exhibits a capacity to bind lysine which is reduced as compared with that of the native plasminogen activator. In a particularly advantageous embodiment, the plasminogen activator exhibits a modified kringle domain, preferably a
35 kringle 2 domain which is modified as compared with that of the native t-PA. This latter domain can be entirely or partially deleted such that the capacity to bind lysine is reduced.

The K2 domain, or regions which are functionally or structurally essentially homologous to it, can advantageously be modified such that lysine residues no longer bind or only bind with low affinity.

5

In a particularly advantageous embodiment, the plasminogen activator which can be employed in accordance with the invention is modified t-PA.

10 The significance of the K2 domain, including the preparation of t-PA K2 deletion mutants, is described in detail in Horrevoets AJ, Smilde A, de Vries C, Pannekoek H (The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in
15 vitro fibrinolysis: Journal of Biological Chemistry, 269, 17, 12639-12644, 1994).

Because their ability to bind lysine is lacking or reduced, the plasminogen-activating factors which can
20 be used in accordance with the invention exhibit an elevated fibrin selectivity and a reduced ability to be activated by fibrinogen or beta-amyloid. This reduced ability to be activated by fibrinogen is probably the cause of the fibrin selectivity. The possession by the
25 plasminogen activator of a high fibrin selectivity is of considerable importance in connection with treating stroke, in particular, since, for example, the native t-PA can be activated by the fibrinogen which overcomes the damaged blood-brain barrier and then stimulates
30 glutamate-mediated excitotoxicity by subsequently activating the NMDA receptors. Accordingly, the reduction, in accordance with the invention, of the ability of the plasminogen activator to be activated by fibrinogen also leads to a reduction in neurotoxicity.

35

The importance of the lysine-binding sites on the t-PA kringle 2 became clear, in particular, as a result of

comparative investigations of the structural and functional domains of t-PA as compared with DSPA. DSPA is a plasminogen activator which was originally isolated from vampire bat saliva (in this regard, see
5 US patent 6,008,019; EP 0 383 417). DSPA can be isolated in four isoforms, of which DSPA α 1 can be prepared recombinantly using CHO cells.

In contrast to t-PA, DSPA only has one kringle domain.
10 This domain corresponds functionally and structurally more closely to the t-PA K1 domain than to the K2 domain and does not possess any lysine-binding sites (Bringmann P, Gruber D, Liese A, Toschi L, Krätzschar J, Schleuning WD, Donner P: Structural
15 features mediating fibrin selectivity of vampire bat plasminogen activators; Journal of Biological Chemistry 1995; 270(43): 25596-25603). There are therefore some statements in the literature to the effect that DSPA does not possess any kringle 2 domain.

20 Furthermore, DSPA is always present as a single-chain molecule since a plasmin activation site as in t-PA is lacking. As compared with t-PA, the activity of DSPA is stimulated about 45 000 times in the presence of fibrin
25 whereas, according to Gardell SJ, Duong LT, Diehl, York JD, Hare TR, Register RB, Jacobs JW, Dixon RA, Friedman PA (Isolation, characterization and c-DNA cloning of a vampire bat salivary plasminogen activator: Journal of Biological Chemistry 1989;
30 264(30): 17947-17952) this value is 205.

A diagram of the structure of DSPA is enclosed as Fig. 2. Fig. 2b shows a comparison of the amino acid sequence of t-PA with that of DSPA (SEQ ID Nos. 1+2).

35 In the past, the ability of t-PA to bind fibrin was attributed functionally to the finger domain and kringle 2 (van Zonnenfeld AJ, Veerman H, Pannekoek H:

(1986) Proc. Natl. Acad. Sci. USA., 83: 4670-4674). However, more recent publications also suggest that the proteinase domain P may have a certain relevance in this regard (Bennett loc. cit.). The functions of the individual domains have also been investigated by Bakker AHF, Jacoline E., Weening-Verhoeffet. D., Verheijen JH (The role of Lysyl-Binding site of tissue type plasminogen activator in the interaction with a forming fibrin clod: Journal of Biological Chemistry 270, 21, 12355-12360, 1995).

Bakker et al. prepared various modifications of t-PA, for example two deletion mutants which lack either the kringle 2, the finger domain or the epidermal growth factor domain. These mutations were also combined and some of them were additionally provided with a point mutation in the kringle 2, namely involving the substitution D236N. This selective amino acid substitution leads to the replacement of the Asp in position 236 with asparagine and thereby to the deletion of the lysine-binding site (LBS in the K2 domain). For the preparation of the mutation, the reader is expressly referred to the abovementioned publication by Bakker et al including the references which are cited therein.

In their investigations, Bakker et al. demonstrated that occupation of the lysine-binding site in the K2 domain by EACA (ϵ -aminocaproic acid) markedly attenuated the binding of the native t-PA to fibrin. The same applied to the modification of the LBS by the D236N substitution except that the attenuation was less. Even the deletion mutant, which consisted solely of the K2 domain and the proteolytic C terminus, still bound to fibrin if only to a slight degree. It was only the K2P mutation, in which the LBS was deleted, which no longer exhibited any fibrin binding.

While these results demonstrate, on the one hand, the importance of the F and K2 domains as well as the LBS in K2, they also demonstrate that the interaction of t-PA of fibrin is not mediated exclusively by the F
5 and K2 domains. Rather, there is also the function of the LBS in the K2 domain, with the LBS presumably being responsible for stabilizing a confirmation of the t-PA which is favorable for binding fibrin.

10 The importance of the K2 domain including its lysine-binding site has also been made clear by investigations carried out by Stewart RJ, Fredenburgh JG and Witz JI (Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with
15 fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E: Journal of Biological Chemistry 273, 29, 18292-18299, 1998).

In binding studies, Stewart et al. investigated, inter
20 alia, the affinities of t-PA and DSPA for fibrin and fibrinogen. In the studies, the affinities were investigated in the presence or absence of the lysine analog EACA in order to analyze the importance of the kringle-dependent interactions. They concluded, from
25 their investigations, that DSPA is unable to bind to fibrinogen because of the lack of the lysine-binding sites in the kringle. They therefore attribute a function, which is essential for the ability of t-PA to bind fibrin, to LBS in the t-PA kringle 2 in
30 combination with the finger domain.

The experimental results reported in Example 1 confirm the different affinities of DSPA α 1 and recombinant human t-PA for the cofactors beta-amyloid (1-42),
35 fibrinogen and fibrin. To obtain these data, the kinetic parameters k_{cat} and K_m , and the k_{cat}/K_m ratio, were determined for each plasminogen activator/cofactor

combination. In the absence of a cofactor, the efficiency of DSPAalphal for plasminogen activation was about 100 times lower than that of t-PA whereas the two compounds were equally efficient in the presence of
5 fibrin. DSPAalphal was about 30 times less effective than t-PA in the presence of the fibrinogen or beta-amyloid cofactor. At a physiological plasminogen concentration of 2 μ M, these data give a ratio for the efficiency of fibrin as cofactor to that of fibrinogen
10 or beta-amyloid as cofactor to be 480 in the case of DSPAalphal and 16 in the case of human t-PA.

As has already been explained above, the plasminogen-activating factor which is employed in accordance with
15 the invention is characterized by the fact that its kringle 2 lysine-binding site is either absent or modified. In one embodiment, the kringle 2 is deleted. However, it is also possible, in another embodiment, to retain the kringle 2 and to substitute the aspartic
20 acid at position 236 with asparagine. Accordingly, it is not crucial for the invention, according to the invention, of the modified t-PA for the kringle structure to be lacking but only for the lysine-binding site to be modified such that an interaction, which
25 increases the activity of the t-PA, with a cofactor is no longer possible.

In another advantageous embodiment, the plasminogen activator, in particular the modified t-PA, which is
30 used can be modified by the deletion of the kringle 1 such that the t-PA is no longer able to bind receptor. As a result, the tissue plasminogen activator is no longer metabolized in the native manner via the liver, resulting in the in-vivo half-life being prolonged
35 (Rijken DC, Otter M, Kuiper J, von Berkel TJC: Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb. Res. 1990; Supel. X: 63-71). Deletion of the kringle 1

is known from reteplase and described, for example, by Martin U, Bader R, Böhm E, Kohnert U, von Möllendorf E, Fischer S, Sponder G (BM 06.022: A Novel recombinant plasminogen activator. Cardiovascular drug reviews
5 1993; 11: 299-311). For this, use is made of mutants in which amino acids 4-176 are deleted. Prolonging the half-life makes it possible to administer the plasminogen activator as a bolus.

10 In a preferred embodiment, the plasminogen activator which can be used in accordance with the invention is based on one of the amino acid sequences shown in Figures 3, 11 or 13. Each of these amino acid sequences constitutes a modified t-PA in which the kringle 2 is
15 deleted and a structural change has been made in the region of the sequence for the t-PA activation cleavage site. This change can either only consist in the replacement of amino acids R and I in the activation cleavage site (e.g. by HS; see sequence SEQ ID No. 3,
20 Fig. 3) or additionally affect adjacent amino acids (e.g. replacement of FRIK with LHST in the sequence SEQ ID No. 4, Fig. 11). The latter modification corresponds to the structure of native DSPA at this point.

25 According to the invention, preference is given to producing, and employing for stroke treatment, a plasminogen activator which, particularly suitably, combines the advantages of native t-PA, namely, in particular, low immunogenicity when used in human
30 patients, with the advantages of DSPA, namely the lack of neurotoxicity. In one embodiment of the invention, the deletion of the t-PA kringle 2 is accordingly selected such that a transition region to the downstream structure is created, which transition region corresponds to the
35 comparable structure in DSPA. The transition region between the remaining kringle 1 domain of the modified t-PA and the downstream cysteine bridge is accordingly advantageously formed by the sequence SKAT. In DSPA,

the sequence SKAT is located between the kringle and the cysteine bridge. This advantageous structure is realized, for example, in the sequence SEQ ID No. 4 as shown in Fig. 11.

5

Fig. 12 (Multiple Sequence Alignment) shows a comparison between t-PA and the two described embodiments in accordance with the invention.

10 In another embodiment according to the invention, use is made of a plasminogen activator as depicted in Figure 13 (SEQ ID No. 5).

It is naturally also possible, in accordance with the
15 invention to use proteins which possess sequences which are homologous with, or partially identical to, the amino acid sequences depicted in Figures 3, 11 and 13. Preference is given to homologies or identities of at least 70, preferably between 80 and 95%. These
20 homologous or identical proteins exhibit the activity of a plasminogen-activating factor (preferably displayed as the release of pNA) and cause a blood clot to the lyse in vitro (see Example 3).

25 The plasminogen activator which can be used in accordance with the invention can be characterized by the lack of the finger and epidermal growth factor domains. This deletion substantially reduces binding to the liver receptors and once again prolongs the half-
30 life (Larson GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB: Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. Journal of biological Chemistry 1991; 266: 8156-8161;
35 Smalling RW: Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 1996; 78 (suppl. 12): 2-7).

Aside from deletion mutants, the plasminogen activators which are employed in accordance with the invention can also be only punctately modified by means of site-directed mutagenesis. Thus, it is known, for example, from rt-PA-TNK (tenecteplase) that three mutations at the binding site for the plasminogen activator inhibitor, on the one hand, and at the binding site by which t-PA binds to liver cells, on the other hand, lead to the catalytic activity being increased while, at the same time, the ability to be inactivated by PAI is decreased. This thereby gives tenecteplase a catalytic conversion constant K_{cat}/K_m which is increased 100-fold (in this regard, see also Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Pena LC, Brady K, Wurm FM, Ogez J, Bennett WF: A slow clearing fibrin-specific, PAI resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemostas 1993; 70: 307-312 and Cannon CP, Love TW, McCabe CH, Kirshenbaum JM, Henry T, Sequira R, Schweifer M, Breed J, Cutler D, Tracy R, for the TIMI investigators. TNK-tissue plasminogen activators in myocardial infarction (TIMI) 10: Results of the initial patients in the TIMI 10 pilot - a phase 1, pharmacokinetics trial. Circulation 1995; 92 (suppl.): 1-415).

EXAMPLE 1:

1. Comparative analysis of the efficiencies of beta-amyloid (1 to 42), fibrinogen and fibrin as cofactors for plasminogen activation by DSPA α and recombinant human t-PA.

Materials and methods

The following substances were used:

- 5 - DSPAalpha1 (prepared by Paion, batch No. 2DSA01,
 12 December 2002, sample 10). 10 mg of the
 substance were dissolved in 10 ml of sterile water
 in order to obtain a final concentration of
 1 mg/ml.
- 10 - Recombinant t-PA (Actilyse®, prepared by Paion,
 batch No. 102572). 10 mg were dissolved in 10 ml
 of sterile water to give a final concentration of
 1 mg/ml.
- 15 - Human Glu-plasminogen, purified from human plasma
 (prepared by Paion) and dissolved in PCA buffer
 at a concentration of 25 µM.
- 20 - Human fibrinogen, essentially plasminogen-free,
 was obtained from Sigma (catalog No. F4883, batch
 12K7620). 25 mg were dissolved in 25 ml of PCA
 buffer to give a final concentration of 1 mg/ml.
- 25 - Human thrombin (Sigma; catalog No. T7009. Batch
 61K7603). 100 U were dissolved in 10 ml of PCA
 buffer to give a concentration of 10 U/ml.
- 30 - Flavigen.pli color reagent (D-but-CHT-Lys-p-
 nitroaniline-DHCL) from Biopool (catalog
 No. 101353, batch 1512016). 100 µM were dissolved
 in 50 ml of PLCR buffer to give a final
 concentration of 2 millimolar.
- 35 - beta-Amyloid protein (1-42) from Bachem (catalog
 No. H-1368, batch 0535120). 4 mg were dissolved in
 4 ml of 0.1 percent ammonium hydroxide to give a
 final concentration of 1 mg/ml.

All reagents were divided into aliquots and stored at
-20°C for no more than two weeks.

PLC Buffer (Jones 1990): 0.1 M NaCl.2H₂O (Acros catalog No. 20779); 0.03 M NaHCO₃ (Acros catalog No. 21712); 4 mM KCl (Fluka, catalog No. 60130); 1 mM CaCl₂.2H₂O (Acros, catalog No. 207780); 1 mM Na₂HPO₄.2H₂O (Fluka, catalog No. 71638); 0.3 mM MgCl₂.6H₂O (Acros, catalog No. 197530); 0.4 mM MgSO₄.7H₂O (Fluka, catalog No. 63140); 20 mM HEPES (Applichem, catalog No. A1969); 0.01% Polysorbate 80 (Fluka, catalog No. 93781).

10 Plasminogen activation assay:

The assay for plasminogen activation was carried out on microtiter plates at a total volume of 0.15 ml, as described by Bringmann et al. (loc. cit.). The reagents were added as follows:

50 µl of plasminogen (0-24 µM); 15 µl of cofactor (1 mg/ml); 10 µl of plasminogen activator 7.5 nM and 75 µl of Flavigen (2 mM).

20

The final concentrations were as follows:

plasminogen activator: (t-PA or DSPAα1): 0.5 nM; Glu-plasminogen; 0.0625, 0.125, 0.25, 0.5, 1, 2, 4 and 8 µM; FlavigenPli: 1 mM and cofactors: 100 µg/ml.

25

The cofactors beta-amyloid (1-42), fibrinogen and fibrin were compared with the control without cofactor. For the control, the reaction mixture contained a further 0.13 units of human thrombin/ml.

30

Directly after the addition, the microtiter plate was introduced, at 25°C, into a molecular device ThermoMax microplate reader.

35

Stirring was carried out from time $t = 0$.

The optical density at 405 nm and 490 nm was measured at regular intervals. The optical densities at 490 nm were subtracted from the optical densities at 405 nm in order to eliminate the differences due to the movement
5 of the liquid. All the experiments were carried out in three repeats using each plasminogen concentration and plasminogen activator concentration.

The K_m and k_{cat} values were determined (Figs. 4-6).

10

Figures 4

- a) Determining the molar extinction of the pNA.
- 15 b) Conversion of the Flavigen.pli by 10 nM plasmin as a function of the Flavigen.pli concentration (in μM).
- c) Michaelis-Menten plot of the conversion of
20 Flavigen by 10 nM plasmin. The initial rates from Fig. 4b were converted into pNA/s.

Figures 5

- 25 Curves of the optical density against the time for four different combinations of plasminogen activators and cofactors. Plasminogen concentrations of 8; 4; 2; 1; 0.5; 0.25; 0.125 and 0.0625 μM were used for this purpose.

30

- a) t-PA without cofactor
- b) t-PA with beta-amyloid (1-42) as cofactor
- 35 c) t-PA with fibrinogen as cofactor
- d) t-PA with fibrin as cofactor

- e) DSPAalphanal without cofactor
- f) DSPAalphanal with beta-amyloid (1-42) as cofactor
- 5 g) DSPAalphanal with fibrinogen as cofactor
- h) DSPAalphanal with fibrin as cofactor

Figures 6

10

Plot of $a \{= k_s \cdot k_{cat} \cdot PA \cdot E \cdot P / (K_m + P)\}$ against the plasminogen concentration

- a) Plots for t-PA without cofactor or beta-amyloid,
15 fibrinogen or fibrin as cofactor
- b) Plots for DSPAalphanal 11.38 without cofactors

Results:

20

Table 1

	$k_{cat}(s^{-1})$	$K_m(\mu M)$	k_{cat}/K_m
t-PA ctrl	n.d.	n.d.	1272 ± 224
t-PA amyl	n.d.	n.d.	9307 ± 579
t-PA fbg	n.d.	n.d.	10204 ± 1546
t-PA fibrin	0.351 ± 0.35	0.178 ± 0.017	$1\ 990\ 000 \pm 327\ 000$
DSPA ctrl	n.d.	n.d.	12.5 ± 0.9
DSPA fbg	$1.649 \pm 0.110e-3$	2.465 ± 0.426	690 ± 181
DSPA amyl	$0.957 \pm 0.199e-3$	0.853 ± 0.316	1304 ± 785
DSPA fibrin	0.532 ± 0.136	1.098 ± 0.382	$506\ 000 \pm 120\ 000$

25 Table 1: Values for k_{cat}/K_m for the activation of plasminogen by recombinant human T-PA or DSPAalphanal using beta-amyloid (1 to 42), fibrinogen or fibrin as cofactors.

The results are given as the mean $\pm$ standard deviation of three independent experiments.

5 It was not possible to determine the precise values for kcat and Km since the Km values were higher than the maximum plasminogen concentration (8 μ M) which it was possible to use.

10 The derivation of the kinetic constants is not on its own sufficient for comparing the efficiencies of the different cofactors since the reaction rates at plasminogen concentrations close to or below the Km values are dependent on the plasminogen concentration. For this reason, the reaction rates are calculated, 15 using Michaelis-Menten kinetics, at physiological plasma plasminogen concentrations at 2 μ M. The relative efficiencies of the different cofactors for plasminogen activation by t-PA and DSPAalpha1 (Table 2) are determined on this basis.

20

Table 2

cofactor	DSPAa1	t-PA
none	1	101.8 $\pm$ 17.9
DSPA amyloid	27.3 $\pm$ 7.7	744.6 $\pm$ 23.6
DSPA fbg	29.8 $\pm$ 5.0	816.3 $\pm$ 123.7
DSPA fibrin	13 560 $\pm$ 2360	12 880 $\pm$ 1360

25 Relative rates of plasminogen activation at the physiological plasminogen concentration of 2 μ M, as calculated using the kinetic parameters in Table 1. The combination of the DSPA control is 1.

EXAMPLE 2:

30

The prion diseases, i.e. the spongiform encephalopathies, are fatal neurodegenerative phenomena which are characterized by an accumulation of the

abnormal isoform of the prion protein (PrP^{sc}) in amyloid deposits. The normal prion protein (PrP^c) is expressed in many tissues, in particular in the brain, in which it is concentrated in the synapses. The mechanism of
5 the change in the conformation of PrP^c to give PrP^{sc} is still not well understood and nor is the mechanism which leads to neurodegeneration by way of PrP^{sc} formation. A possible mechanism could lie in an effect on PrP^{sc} in connection with the activation of
10 plasminogen by t-PA.

We have already shown, using a recombinant protein, that PrP can increase t-PA-catalyzed plasminogen activation 300-fold (Ellis V, Daniels M, Misra R,
15 Brown DR (2000): Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner, *Biochemistry* 41: 6891-6896).

The ability of PrP to stimulate plasminogen activation
20 was dependent on the conformation of the PrP, with the conformation being influenced by the presence or absence of Cu²⁺. The latter form contains a large number of beta structures which correspond to the PrP^{sc} isoform and stimulate plasminogen activation. These data agreed
25 with earlier observations that, while plasminogen bound to PrP^{sc} which was isolated from scrapie-infected mouse brains, it did not bind to PrP^c as normal brain cells (Fischer M, Roeckl C, Rarizek P, Schwarz HP, Aguzzi A (2000): Binding of disease-associated prion protein to
30 plasminogen. *Nature* 408: 479-483).

Furthermore, our experiments have shown that the mechanism of PrP-stimulated plasminogen activation also encompasses the binding of t-PA to apoPrP (i.e. PrP
35 without Cu²⁺). The structures which are required for this binding have not yet been evaluated in detail. However, the binding is specific since it was prevented by DFP-inactivated t-PA.

Other methods:

The PrP batches which were used in these investigations
5 were in each case derived from recombinant murine PrP
isolated from E. coli. Following the purification of
the His-labeled PrP, the protein folds once again, in
the absence or presence of copper chloride, in order to
form either a holo-PrP or an apo-PrP. Aggregated forms
10 of these proteins are in each case produced by rapid
dissolution in water. The protein was collected by
centrifugation. The material is resistant to proteinase
K digestion. A mutant $\Delta 51-90$ form, which does not
comprise the Cu^{2+} binding site, was prepared in the same
15 way. The effect of these different forms of PrP on
plasminogen activation by DSPA was investigated by
incubating the PrP (0-100 $\mu\text{g}/\text{m}$) with Lys-plasminogen
(25 nm) and DSPA (0.25 nm). Plasminogen activation is
determined by hydrolysis of the plasmin-specific dye
20 H-d-Val-Leu-Lys-7-amido-4-methylcoumarin at 37°C using
the SPECTRAMax Gemini-lourescence microplate reader.
The controls of these experiments contain sc-t-PA, as a
positive control for the effect of the PrP on
plasminogen activation, and fibrin fragments, as a
25 positive control for stimulation of the t-PA and DSPA
activities.

The specificity of the plasminogen binding was
determined by competition with DFP-inactivated t-Pa.
30 The lysine analog EACA was also used as a competitive
inhibitor.

Results:

35 The results of the experiments are presented in Table 3
and Figs. 7 to 10.

Fig. 7, in particular, provides informative insight. This figure makes clear that PrP specifically only activates t-PA and not DSPA. It was furthermore made clear that the lysine-binding site of the kringle 2 must, as the essential difference between DSPA and t-PA, be involved. Table 3

Reaction rates, M-ls-l

		minus PrP	plus PrP	PrP + Hep	fibrin
PrP preparation #1					
	tPA	7200	1 800 000		2 000 000
	DSPA	15.3	9.77		2 000 000
PrP preparation #2					
	tPA	7020	624 000	2 912 000	
	DSPA	15.75	162.75	5 565	

10 **Fold stimulation**

		minus PrP	plus PrP	PrP + Hep	fibrin
PrP preparation #1					
	tPA	1	250		2 777 778
	DSPA	1	0.638562		130 719
PrP preparation #2					
	tPA	1	88.88889	414.8148	
	DSPA	1	10.33333	353.3333	

EXAMPLE 3:

- 15 **a. Preparing and purifying humanized DSPA (humDSPA)
(amino acid sequence as depicted in Fig. 11)**

Recombinant human DSPA baculovirus DNA was prepared using the Bac-to-Bac system (Invitrogen) and the purified virus DNA was transfected into Sf9 insect cells. The recombinant baculovirus which was produced was amplified using Sf9 cells. HumDSAP was expressed using High Five insect cells in serum-free medium in suspension culture. The cell culture supernatant

containing the recombinant protein was frozen at -20°C until it was subjected to further working up.

5 The cell culture supernatant was thawed slowly at RT on a shaker and then centrifuged at 4000 x g for 1 hour. The protein solution (1.5 l) was equilibrated to pH 6.0 with 50 mM ammonium acetate, loaded onto an SP-sepharose XL (Amersham) ion exchange column (350 ml bed volume) and washed with 5 column volumes of 50 mM
10 ammonium acetate solution. The bound protein was eluted in a gradient of 0-100% 1M ammonium acetate, pH 6, over 10 column volumes.

HumDSPA-containing fractions were identified by Western
15 blotting; following protein determination, these fractions were subjected to an activity test, frozen at -80°C and subsequently lyophilized.

In contrast to the standard activity assay, 50 µl of
20 eluate (= humDSPA-containing fraction), 50 µl of 0.2 M Tris, pH 8.0, and 100 µl of 2 mM S-2288 in PBS were used in this experiment.

b. Assay of DSPA activity

25 The activity assay employed is the determination of the rate at which a plasminogen activator converts the colorless substrate S-2288 into a colored product. The assay is a standard method for determining the
30 proteolytic activity of plasminogen-activating factors. The activity is visualized by determining the release of a chromogen (p-nitroaniline, pNA) by the test substance. The Chromogenix company offers the chromogen S-2288 for this purpose.

35 In this assay, the rate of reaction is not determined directly (e.g. in catal units); instead, comparison is made with a standard which is defined as 100% activity.

The reaction rate was measured in a buffer having the following composition: 25 mM Tris-HCl, pH 8/0.1% albumin/100 mM NaCl/1.1 mM glycine/1.2 mM mannitol/2.5 mM S-2288.

The measurement was carried out in a 96-well plate using blank values, standards and samples containing different concentrations of protein.

10

The increase with time in the absorption at 405 nm was recorded using a photometer. The slope of the linear portion of the curve was determined using Excel. This gives the activity.

15

Fig. 14 shows the activities of the fractions (expressed in S-2288 activity). The silver-stained gels can be seen in Figs. 15a and 15b. Figs. 16a and 16b show the Western blots. The protein detected in the Western blot corresponds to the protein marked with the arrowhead in the silver-stained gel.

20

[L = load; T=flow-through; W = wash; 0-40% B, A2, A3 ... fractions]

25

EXAMPLE 4:

Clot lysis (thrombolytic activity)

The residue of the humDSPA-containing fraction B6 was dissolved in 15 ml of PBS and the solution was centrifuged at 4000 × g for 15 min. This fraction was selected since it exhibited the highest purity. An aliquot was removed and used for the activity determination. The catalytic activity of this sample was roughly comparable to the catalytic activity of 5 µg of activase/ml.

30

35

The blood clots which were used were derived from a normal blood sample taken 24 h earlier and were in each case formed from 2 ml of blood which was transferred into polypropylene tubes and coagulated under natural
5 conditions. The lysis was carried out in PBS.

The humDSPA-containing fraction B6 (from the SPXL-sepharose capture step) was first of all lyophilized. The residue was dissolved in 15 ml of PBS and
10 centrifuged at 4000 g for 15 min. A sample of this solution was removed for an S-2288 activity determination before the blood clot was added. The catalytic activity of this sample corresponded essentially to the catalytic activity of 5 µg of
15 activase/ml.

Figures 17a to 17d show the results of the chronological course of the clot lysis at 0 h, 3 h, 4 h and 24 h after adding the humDSPA. The left-hand
20 experimental assay in each case shows the control. PBS containing humDSPA in the above-described quantity is present in the right-hand assays.

The blood cells slowly sediment out of the
25 disintegrating clot. A type of mesh, which can already be discerned after 4 h, remains after 24 h. In the assay, detached blood cells were aspirated after 4 h using a syringe in order to view the structure of the remaining clot.

30

Consideration has to be given to the fact that the fibrinolysis slows down when the clot is no longer hanging in its own lysate. This is the reason why any clot at all is still present after 24 h.

35

It is not possible to quantify this reaction. However, the humDSPA exhibits a marked increase in activity as compared with native DSPA since at least 4 times the

- 24 -

quantity of DSPA has to be used in order to dissolve a clot of the same size.

Patent claims

1. The use of a plasminogen activator which has a lysine-binding capacity which is reduced as compared with that of the native t-PA for treating thrombotic diseases, in particular stroke, whereas the t-PA activation site is modified in the amino acid positions R15-I16 of the plasminogen activator, and said activation site exhibits a LHST sequence.
2. The use as claimed in claim 1, **characterized by** a modification of the plasminogen activator at kringle 2 or domains which are functionally or structurally homologous therewith.
3. The use as claimed in claim 2, **characterized by** a deletion of kringle 2 or domains which are structurally or functionally homologous therewith.
4. The use as claimed in claim 2, **characterized by** a modification of the kringle 2 lysine-binding sites or domains which are structurally or functionally homologous therewith.
5. The use as claimed in claim 4, **characterized by** the substitution D236N or of amino acids which are homologous therewith.
6. The use as claimed in one of the preceding claims, **characterized in that** the plasminogen activator exhibits an homology of at least 75% with t-PA.
7. The use of a plasminogen activator which has a lysine-binding capacity which is reduced as compared with that of the native t-PA for treating thrombotic diseases, in particular stroke, **characterized in that**, in the transition region between the kringle and the cysteine bridge, the plasminogen activator exhibits an amino acid sequence segment containing SKAT.
8. A plasminogen activator comprising an amino acid sequence as depicted in one of the Figures 3, 11 and 13.
9. A plasminogen activator, **characterized by** an identity of at least 70%, preferably an identity of from 80 to 90%, particularly preferably an identity of 95%, with a plasminogen activator as claimed in one of the preceding claims.
10. A plasminogen activator as claimed in one of claims 7 to 9, **characterized by** a thrombolytic activity which is increased as compared with that of the native DSPA.

SEQUENCE LISTING

<110> Paion GmbH
 <120> Plasminogen-Aktivatoren mit verringerter Lysin-Bindungska-
 pazität
 <130> 46 029 K
 <140> PCT/EP2004/010220
 <141> 2004-09-13
 <150> DE 103 42 518.7
 <151> 2003-09-12
 <160> 5
 <170> PatentIn version 3.3
 <210> 1
 <211> 562
 <212> PRT
 <213> Homo sapiens
 <400> 1

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gln Glu Ile His Ala Arg Phe Arg Arg
 20 25 30

Gly Ala Arg Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met
 35 40 45

Ile Tyr Gln Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn
 50 55 60

Arg Val Glu Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser
 65 70 75 80

Val Pro Val Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr
 85 90 95

Cys Gln Gln Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu
 100 105 110

Gly	Phe	Ala	Gly	Lys	Cys	Cys	Glu	Ile	Asp	Thr	Arg	Ala	Thr	Cys	Tyr	115	120	125	
Glu	Asp	Gln	Gly	Ile	Ser	Tyr	Arg	Gly	Thr	Trp	Ser	Thr	Ala	Glu	Ser	130	135	140	
Gly	Ala	Glu	Cys	Thr	Asn	Trp	Asn	Ser	Ser	Ala	Leu	Ala	Gln	Lys	Pro	145	150	155	160
Tyr	Ser	Gly	Arg	Arg	Pro	Asp	Ala	Ile	Arg	Leu	Gly	Leu	Gly	Asn	His	165	170	175	
Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Arg	Asp	Ser	Lys	Pro	Trp	Cys	Tyr	Val	180	185	190	
Phe	Lys	Ala	Gly	Lys	Tyr	Ser	Ser	Glu	Phe	Cys	Ser	Thr	Pro	Ala	Cys	195	200	205	
Ser	Glu	Gly	Asn	Ser	Asp	Cys	Tyr	Phe	Gly	Asn	Gly	Ser	Ala	Tyr	Arg	210	215	220	
Gly	Thr	His	Ser	Leu	Thr	Glu	Ser	Gly	Ala	Ser	Cys	Leu	Pro	Trp	Asn	225	230	235	240
Ser	Met	Ile	Leu	Ile	Gly	Lys	Val	Tyr	Thr	Ala	Gln	Asn	Pro	Ser	Ala	245	250	255	
Gln	Ala	Leu	Gly	Leu	Gly	Lys	His	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	260	265	270	
Asp	Ala	Lys	Pro	Trp	Cys	His	Val	Leu	Lys	Asn	Arg	Arg	Leu	Thr	Trp	275	280	285	
Glu	Tyr	Cys	Asp	Val	Pro	Ser	Cys	Ser	Thr	Cys	Gly	Leu	Arg	Gln	Tyr	290	295	300	
Ser	Gln	Pro	Gln	Phe	Arg	Ile	Lys	Gly	Gly	Leu	Phe	Ala	Asp	Ile	Ala	305	310	315	320

Ser His Pro Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro
 325 330 335

Gly Glu Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile
 340 345 350

Leu Ser Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu
 355 360 365

Thr Val Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu
 370 375 380

Gln Lys Phe Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp
 385 390 395 400

Asp Thr Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser
 405 410 415

Ser Arg Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro
 420 425 430

Pro Ala Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly
 435 440 445

Tyr Gly Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys
 450 455 460

Glu Ala His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His
 465 470 475 480

Leu Leu Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr
 485 490 495

Arg Ser Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp
 500 505 510

Ser Gly Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val
 515 520 525

Gly Ile Ile Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly
530 535 540

Val Tyr Thr Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met
545 550 555 560

Arg Pro

<210> 2
<211> 477
<212> PRT
<213> Desmodus rotundus

<400> 2

Met Val Asn Thr Met Lys Thr Lys Leu Leu Cys Val Leu Leu Leu Cys
1 5 10 15

Gly Ala Val Phe Ser Leu Pro Arg Gln Glu Thr Tyr Arg Gln Leu Ala
20 25 30

Arg Gly Ser Arg Ala Tyr Gly Val Ala Cys Lys Asp Glu Ile Thr Gln
35 40 45

Met Thr Tyr Arg Arg Gln Glu Ser Trp Leu Arg Pro Glu Val Arg Ser
50 55 60

Lys Arg Val Glu His Cys Gln Cys Asp Arg Gly Gln Ala Arg Cys His
65 70 75 80

Thr Val Pro Val Asn Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly
85 90 95

Thr Cys Trp Gln Ala Val Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro
100 105 110

Ala Gly Tyr Thr Gly Lys Arg Cys Glu Val Asp Thr Arg Ala Thr Cys
115 120 125

Tyr Glu Gly Gln Gly Val Thr Tyr Arg Gly Thr Trp Ser Thr Ala Glu
 130 135 140

Ser Arg Val Glu Cys Ile Asn Trp Asn Ser Ser Leu Leu Thr Arg Arg
 145 150 155 160

Thr Tyr Asn Gly Arg Met Pro Asp Ala Phe Asn Leu Gly Leu Gly Asn
 165 170 175

His Asn Tyr Cys Arg Asn Pro Asn Gly Ala Pro Lys Pro Trp Cys Tyr
 180 185 190

Val Ile Lys Ala Gly Lys Phe Thr Ser Glu Ser Cys Ser Val Pro Val
 195 200 205

Cys Ser Lys Ala Thr Cys Gly Leu Arg Lys Tyr Lys Glu Pro Gln Leu
 210 215 220

His Ser Thr Gly Gly Leu Phe Thr Asp Ile Thr Ser His Pro Trp Gln
 225 230 235 240

Ala Ala Ile Phe Ala Gln Asn Arg Arg Ser Ser Gly Glu Arg Phe Leu
 245 250 255

Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Val Leu Thr Ala Ala His
 260 265 270

Cys Phe Gln Glu Ser Tyr Leu Pro Asp Gln Leu Lys Val Val Leu Gly
 275 280 285

Arg Thr Tyr Arg Val Lys Pro Gly Glu Glu Glu Gln Thr Phe Lys Val
 290 295 300

Lys Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr Asn Asn
 305 310 315 320

Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Pro Gln Cys Ala Gln
 325 330 335

Glu Ser Asp Ser Val Arg Ala Ile Cys Leu Pro Glu Ala Asn Leu Gln
 340 345 350

Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys His Lys
 355 360 365

Ser Ser Ser Pro Phe Tyr Ser Glu Gln Leu Lys Glu Gly His Val Arg
 370 375 380

Leu Tyr Pro Ser Ser Arg Cys Ala Pro Lys Phe Leu Phe Asn Lys Thr
 385 390 395 400

Val Thr Asn Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly Glu Ile
 405 410 415

Tyr Pro Asn Val His Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu
 420 425 430

Val Cys Met Asn Asp Asn His Met Thr Leu Leu Gly Ile Ile Ser Trp
 435 440 445

Gly Val Gly Cys Gly Glu Lys Asp Val Pro Gly Val Tyr Thr Lys Val
 450 455 460

Thr Asn Tyr Leu Gly Trp Ile Arg Asp Asn Met His Leu
 465 470 475

<210> 3

<211> 480

<212> PRT

<213> artificial

<220>

<223> deletierter Kringel-2, AS 311/312: RI -> HS

<400> 3

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gln Glu Ile His Ala Arg Phe Arg Arg

20	25	30
Gly Ala Arg Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met		
35	40	45
Ile Tyr Gln Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn		
50	55	60
Arg Val Glu Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser		
65	70	75
Val Pro Val Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr		
85	90	95
Cys Gln Gln Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu		
100	105	110
Gly Phe Ala Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr		
115	120	125
Glu Asp Gln Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser		
130	135	140
Gly Ala Glu Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro		
145	150	155
Tyr Ser Gly Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His		
165	170	175
Asn Tyr Cys Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val		
180	185	190
Phe Lys Ala Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys		
195	200	205
Ser Glu Gly Asn Ser Asp Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln		
210	215	220
Pro Gln Phe His Ser Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His		

225		230		235		240
Pro Trp Gln Ala	Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu	245		250		255
Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser		260		265		270
Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val		275		280		285
Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys		290		295		300
Phe Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr		305		310		315
Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg		325		330		335
Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala		340		345		350
Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly		355		360		365
Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala		370		375		380
His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu		385		390		395
Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser		405		410		415
Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly		420		425		430
Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile						

435

440

445

Ile Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr
 450 455 460

Thr Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
 465 470 475 480

<210> 4

<211> 476

<212> PRT

<213> artificial

<220>

<223> deletierter Kringel-2, AS 310-313: FRIK -> LHST

<400> 4

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gln Glu Ile His Ala Arg Phe Arg Arg
 20 25 30

Gly Ala Arg Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met
 35 40 45

Ile Tyr Gln Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn
 50 55 60

Arg Val Glu Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser
 65 70 75 80

Val Pro Val Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr
 85 90 95

Cys Gln Gln Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu
 100 105 110

Gly Phe Ala Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr
 115 120 125

Glu Asp Gln Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser
 130 135 140

Gly Ala Glu Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro
 145 150 155 160

Tyr Ser Gly Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His
 165 170 175

Asn Tyr Cys Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val
 180 185 190

Phe Lys Ala Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys
 195 200 205

Ser Lys Ala Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro Gln Leu His
 210 215 220

Ser Thr Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro Trp Gln Ala
 225 230 235 240

Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg Phe Leu Cys
 245 250 255

Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala Ala His Cys
 260 265 270

Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile Leu Gly Arg
 275 280 285

Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe Glu Val Glu
 290 295 300

Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr Asp Asn Asp
 305 310 315 320

Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys Ala Gln Glu
 325 330 335

Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp Leu Gln Leu
340 345 350

Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys His Glu Ala
355 360 365

Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His Val Arg Leu
370 375 380

Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn Arg Thr Val
385 390 395 400

Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly Gly Pro Gln
405 410 415

Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu Val
420 425 430

Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile Ser Trp Gly
435 440 445

Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr Lys Val Thr
450 455 460

Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
465 470 475

<210> 5
<211> 476
<212> PRT
<213> artificial

<220>
<223> deletierter Kringel-2

<400> 5

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15

Ala Val Phe Ser Leu Pro Ser Gln Glu Thr His Arg Gln Leu Ala Arg

20										25					30															
Gly	Ser	Arg	Ala	Tyr	Gln	Val	Ala	Cys	Arg	Asp	Glu	Ile	Thr	Gln	Met															
		35					40					45																		
Ile	Tyr	Gln	Gln	His	Gln	Ser	Trp	Leu	Arg	Pro	Val	Leu	Arg	Ser	Lys															
	50					55					60																			
Arg	Val	Glu	His	Cys	Gln	Cys	Asn	Arg	Gly	Gln	Ala	Arg	Cys	His	Ser															
65					70					75					80															
Val	Pro	Val	Lys	Ser	Cys	Ser	Glu	Pro	Arg	Cys	Phe	Asn	Gly	Gly	Thr															
				85					90					95																
Cys	Trp	Gln	Ala	Leu	Tyr	Phe	Ser	Asp	Phe	Val	Cys	Gln	Cys	Pro	Glu															
			100					105					110																	
Gly	Tyr	Thr	Gly	Lys	Cys	Cys	Glu	Ile	Asp	Thr	Arg	Ala	Thr	Cys	Tyr															
		115					120					125																		
Glu	Gly	Gln	Gly	Ile	Ser	Tyr	Arg	Gly	Thr	Trp	Ser	Thr	Ala	Glu	Ser															
	130					135					140																			
Arg	Val	Glu	Cys	Thr	Asn	Trp	Asn	Ser	Ser	Leu	Leu	Thr	Arg	Arg	Thr															
145					150					155					160															
Tyr	Asn	Gly	Arg	Met	Pro	Asp	Ala	Phe	Asn	Leu	Gly	Leu	Gly	Asn	His															
				165					170					175																
Asn	Tyr	Cys	Arg	Asn	Pro	Asn	Gly	Ala	Pro	Lys	Pro	Trp	Cys	Tyr	Val															
			180					185					190																	
Ile	Lys	Ala	Gly	Lys	Phe	Ser	Ser	Glu	Ser	Cys	Ser	Val	Pro	Ala	Cys															
		195					200					205																		
Ser	Lys	Ala	Thr	Cys	Gly	Leu	Arg	Lys	Tyr	Lys	Glu	Pro	Gln	Leu	His															
	210					215					220																			
Ser	Thr	Gly	Gly	Leu	Phe	Thr	Asp	Ile	Ala	Ser	His	Pro	Trp	Gln	Ala															

225		230		235		240									
Ala	Ile	Phe	Ala	Gln	His	Arg	Arg	Ser	Ser	Gly	Glu	Arg	Phe	Leu	Cys
			245					250						255	
Gly	Gly	Ile	Leu	Ile	Ser	Ser	Cys	Trp	Ile	Leu	Ser	Ala	Ala	His	Cys
			260					265					270		
Phe	Gln	Glu	Ser	Tyr	Leu	Pro	Asp	Gln	Leu	Lys	Val	Val	Leu	Gly	Arg
	275						280					285			
Thr	Tyr	Arg	Val	Val	Pro	Gly	Glu	Glu	Glu	Gln	Thr	Phe	Lys	Val	Lys
	290					295					300				
Lys	Tyr	Ile	Val	His	Lys	Glu	Phe	Asp	Asp	Asp	Thr	Tyr	Asp	Asn	Asp
305					310					315					320
Ile	Ala	Leu	Leu	Gln	Leu	Lys	Ser	Asp	Ser	Pro	Gln	Cys	Ala	Gln	Glu
				325					330					335	
Ser	Asp	Ser	Val	Arg	Ala	Ile	Cys	Leu	Pro	Glu	Ala	Asn	Leu	Gln	Leu
			340					345					350		
Pro	Asp	Trp	Thr	Glu	Cys	Glu	Leu	Ser	Gly	Tyr	Gly	Lys	His	Glu	Ser
		355					360					365			
Ser	Ser	Pro	Phe	Tyr	Ser	Glu	Gln	Leu	Lys	Glu	Gly	His	Val	Arg	Leu
	370					375					380				
Tyr	Pro	Ser	Ser	Arg	Cys	Ala	Pro	Lys	Phe	Leu	Phe	Asn	Arg	Thr	Val
385					390					395					400
Thr	Asn	Asn	Met	Leu	Cys	Ala	Gly	Asp	Thr	Arg	Ser	Gly	Glu	Ile	Tyr
				405					410					415	
Pro	Asn	Val	His	Asp	Ala	Cys	Gln	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Val
			420					425					430		
Cys	Met	Asn	Asp	Asn	His	Met	Thr	Leu	Val	Gly	Ile	Ile	Ser	Trp	Gly

435

440

445

Val Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr Lys Val Thr
 450 455 460

Asn Tyr Leu Gly Trp Ile Arg Asp Asn Met His Leu
 465 470 475